Sylentis announces the results of tivanisiran for dry eye syndrome

(Pharmamar) The studies carried out with tivanisiran showed an improvement in the inflammatory ocular parameters, tear quality, and a reduction in ocular pain, that is associated with dry eye syndrome.

Comments
%d bloggers like this: